Millipore Sigma Vibrant Logo

505486 Pramipexole Dihydrochloride - CAS 104632-25-9 - Calbiochem

Pramipexole Dihydrochloride is a non-ergot Dopamine receptor agonist with selectivity for the D3 receptor. Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Pramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-Nʹ-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride

Primary Target: D3
505486
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
104632-25-9C₁₀H₁₇N₃S•2HCl

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.05486.0001
Retrieving availability...
—
Fulfilment and delivery delayed Fulfilment and delivery delayed
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewNon-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100 mM water and 100 mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
      Catalogue Number505486
      Brand Family Calbiochem®
      SynonymsPramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-Nʹ-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride
      References
      ReferencesAntonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
      Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.
      Product Information
      CAS number104632-25-9
      FormWhite solid
      Hill FormulaC₁₀H₁₇N₃S•2HCl
      Chemical formulaC₁₀H₁₇N₃S•2HCl
      Structure formula ImageStructure formula Image
      Applications
      Biological Information
      Primary TargetD3
      Primary Target K<sub>i</sub>0.5 nM
      Purity≥99% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Pramipexole Dihydrochloride - CAS 104632-25-9 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Antonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
      Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision30-August-2013 JSW
      SynonymsPramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-Nʹ-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride
      DescriptionNon-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100 mM water and 100 mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
      FormWhite solid
      CAS number104632-25-9
      Chemical formulaC₁₀H₁₇N₃S•2HCl
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityH₂O (100 mM)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesAntonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
      Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.